Page last updated: 2024-12-05

hempa

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hempa: A chemosterilant agent that is anticipated to be a carcinogen. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12679
CHEMBL ID3187047
CHEBI ID24565
SCHEMBL ID3277
MeSH IDM0010186

Synonyms (117)

Synonym
tris-(dimethylamid) kyseliny fosforecne
hexamethylfosforamid
phoric triamide, hexamethyl-
unii-m42tu5843z
m42tu5843z ,
hexamethylphosphoramid
CHEBI:24565 ,
hexamethylphosphorsaeuretriamid
n,n,n',n',n'',n''-hexamethylphosphorotriamide
630-31-9
nsc-7967
nsc7967
n,n,n',n',n,n'-hexamethylphosphorotriamide
((ch3)2n)3po
n,n,n,n,n, n-hexamethylphosphoric triamide
n-[bis(dimethylamino)phosphoryl]-n-methyl-methanamine
hexamethylphosphoric triamide
eastman inhibitor hpt
tris(dimethylamino)phosphorus oxide
hmpa
hexamethylphosphoramide
hmpta
ent 50,882
680-31-9
hempa
phosphoric acid hexamethyltriamide
HPT ,
phosphoric triamide, hexamethyl-
hexamethylphosphorotriamide
hexamethylphosphotriamide
phosphoric hexamethyltriamide
wln: 1n1&po&n1&1&n1&1
tris(dimethylamino)phosphine oxide
hexamethylphosphoric acid triamide
hexametapol
phosphoric tris(dimethylamide)
nsc113131
hexamethylorthophosphoric triamide
phosphoryl hexamethyltriamide
nsc-113131
n,n,n,n,n-hexamethylphosphoric triamide
inchi=1/c6h18n3op/c1-7(2)11(10,8(3)4)9(5)6/h1-6h
n,n,n',n',n'',n''-hexamethylphosphoric triamide
hexamethylphophoric triamide
phosphoric triamide, n,n,n',n',n'',n''-hexamethyl-
n,n,n,n,n,n-hexamethylphosphoric triamide
tris-(dimethylamid) kyseliny fosforecne [czech]
ent 50882
einecs 211-653-8
ccris 332
nsc 7967
hexamethyl phosphoramide
nsc 113131
ai3-50882
hexamethylfosforamid [czech]
hsdb 2031
hexamethylphosphoramide, 99%
NCGC00164320-01
hexamethylphosphoramide, purum, >=98.0% (gc)
n-[bis(dimethylamino)phosphoryl]-n-methylmethanamine
H0095
AKOS000120202
A835982
NCGC00164320-02
hexamethyl phosphoric triamide
C19250
dtxcid60694
dtxsid6020694 ,
cas-680-31-9
tox21_302785
NCGC00256318-01
NCGC00259386-01
tox21_201837
c6h18n3op
FT-0627025
ent-50882
hexamethylphosphoramide [hsdb]
hmpa [mi]
hexamethylphosphoramide [iarc]
hexamethylphosphoramide triamide
STL268870
BP-21334
SCHEMBL3277
hexamethyl-phosphoric acid triamide
hexamethyl phosphorictriamide
hexamethylphos-phoramide
hexamethyl-phosphoramide
hexamethylphosphor-amide
hexamethylpho-sphoramide
hexamethyiphosphoramide
hexamethylphosphoric cid triamide
hexamethylphosphoric-triamide
hexamethyl phosphoric acid triamide
hex amethylphosphoramide
hexarnethylphosphoramide
phosphoric-tris-(dimethylamide)
hexamethylphosphorictriamide
hexamethyltriamidophosphate
mfcd00008303
[bis(dimethylamino)phosphoryl]dimethylamine
STR04996
tri(dimethylamino)phosphineoxide
hexamethyl phosphorotriamide
hexmethylphosphoramide
CHEMBL3187047
J-521457
F1908-0085
hexamethylphosphoramide, absolute, over molecular sieve (h2o <=0.01%), >=98.0% (gc)
D78004
hexamethylphosphamide
Q416086
tris(dimethylamino)oxophosphorane
CS-0017155
n-bis(dimethylamino)phosphoryl-n-methyl-methanamine
AMY19097
EN300-17081
ethyl pentafluorophenylglycinate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, the intricate molecular mechanisms underlying the bioaccessibility and bioavailability profile following HMPA intake and the substantial modulation of metabolic homeostasis by HMPA require further elucidation."( 3-(4-Hydroxy-3-methoxyphenyl) propionic acid contributes to improved hepatic lipid metabolism via GPR41.
Iwasa, M; Kawakami, H; Kimura, I; Kuwahara, H; Masujima, Y; Nishikawa, S; Nishitani, Y; Ohue-Kitano, R, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" No dose-response relationship was found between 2 and 4 mg of HMPA per ml and colonization."( Chronic colonization of rat airways with Pseudomonas aeruginosa.
Boyd, RL; Mangos, JA; Ramphal, R; Rice, R, 1983
)
0.27
" The strains have been evaluated in terms of spontaneous frequencies of mosaic eyes, lowest effective dose and dose-response relationship."( The w/w+ SMART is a useful tool for the evaluation of pesticides.
Aguirrezabalaga, I; Comendador, MA; SantamarĂ­a, I, 1994
)
0.29
" Fifty percent effective doses (ED50) to block propagated compound action potentials (AP's) were obtained by examining dose-response relations for each solute."( An analysis of dimethylsulfoxide-induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes.
Gasser, K; Hahin, R; Larsen, J, 1996
)
0.29
" This paper summarizes some of the critical attributes of the hazard identification and dose-response aspects of risk assessments for nasal carcinogens that must be accounted for by risk assessors in order to make informed decisions."( Critical factors in assessing risk from exposure to nasal carcinogens.
Bogdanffy, MS; Harman, AE; Kuykendall, JR; Mathison, BH, 1997
)
0.3
" Another group of rats was implanted subcutaneously with HMPA-filled osmotic minipumps, designed to deliver a dosage of 40 mg/kg/day to prevent the possibility of direct contact of HMPA with the nasal epithelium."( Subchronic nasal toxicity of hexamethylphosphoramide administered to rats orally for 90 days.
Keller, DA; Lee, KP; Marshall, CE, 1997
)
0.3
" In principle, peripheral blood lymphocytes would be expected to accumulate DNA damage with repeated dosing because the majority are not in active division and appear to have limited DNA repair capability, and they are exposed to plasma levels of test materials and metabolites."( Chromosome aberration frequency in rat peripheral lymphocytes increases with repeated dosing with hexamethylphosphoramide or cyclophosphamide.
Doherty, AT; Hayes, J; Holme, P; O'Donovan, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
insect sterilantA chemosterilant intended to sterilize insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
phosphoramideA compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency56.73660.000229.305416,493.5996AID1259244; AID743069; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency27.36400.001024.504861.6448AID743212
activating transcription factor 6Homo sapiens (human)Potency1.54860.143427.612159.8106AID1159516
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency76.95880.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency76.95880.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (34.26)18.7374
1990's23 (21.30)18.2507
2000's19 (17.59)29.6817
2010's19 (17.59)24.3611
2020's10 (9.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.91 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index72.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (6.31%)6.00%
Case Studies1 (0.90%)4.05%
Observational0 (0.00%)0.25%
Other103 (92.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]